Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377096 | 0.88 | PLK4 (0.55) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7135626 | 0.86 | MDM2 (0.50) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5361064 | 0.85 | RAF1 (0.46) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5368427 | 0.85 | MDM2 (0.53) | LRRK2PDGFRBMDM2RPS6KA3 | |
| SCHEMBL5367333 | 0.84 | NOX4 (0.58) | PDGFRB | |
| SCHEMBL5363513 | 0.84 | LRRK2 (0.55) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5374178 | 0.82 | MAP3K7 (0.48) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5366299 | 0.82 | LRRK2 (0.53) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7140932 | 0.82 | PSEN1 (0.62) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7137229 | 0.82 | MAP3K7 (0.50) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| US-6506763-B2 | Useful in prevention and treatment of protein kinase related disorders such as cancer | SUGEN, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | LRRK2 289/4885PSEN1 3695/4885PSEN2 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.